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Identification of oncogenic driver
mutations by genome-wide CRISPR-Cas9
dropout screening
Michael K. Kiessling1, Sven Schuierer2, Silke Stertz3, Martin Beibel2, Sebastian Bergling2, Judith Knehr2,
Walter Carbone2, Cheryl de Vallière1, Joelle Tchinda4, Tewis Bouwmeester2, Klaus Seuwen2, Gerhard Rogler1*†
and Guglielmo Roma2*†
Abstract
Background: Genome-wide CRISPR-Cas9 dropout screens can identify genes whose knockout affects cell viability.
Recent CRISPR screens detected thousands of essential genes required for cellular survival and key cellular
processes; however discovering novel lineage-specific genetic dependencies from the many hits still remains a
challenge.
Results: To assess whether CRISPR-Cas9 dropout screens can help identify cancer dependencies, we screened two
human cancer cell lines carrying known and distinct oncogenic mutations using a genome-wide sgRNA library. We
found that the gRNA targeting the driver mutation EGFR was one of the highest-ranking candidates in the EGFR-
mutant HCC-827 lung adenocarcinoma cell line. Likewise, sgRNAs for NRAS and MAP2K1 (MEK1), a downstream
kinase of mutant NRAS, were identified among the top hits in the NRAS-mutant neuroblastoma cell line CHP-212.
Depletion of these genes targeted by the sgRNAs strongly correlated with the sensitivity to specific kinase inhibitors
of the EGFR or RAS pathway in cell viability assays. In addition, we describe other dependencies such as TBK1 in
HCC-827 cells and TRIB2 in CHP-212 cells which merit further investigation.
Conclusions: We show that genome-wide CRISPR dropout screens are suitable for the identification of oncogenic
drivers and other essential genes.
Keywords: Whole genome CRISPR screen, Dropout, Negative selection, Driver mutations, EGFR, NRAS, Kinase
Background
The RNA-guided CRISPR (clustered regularly inter-
spaced short palindrome repeats)-associated nuclease
Cas9 has become a powerful and versatile tool to study
the functional relevance of genes in biological processes
and disease settings [1–7]. Cas9 and a single guide RNA
(sgRNA) cause DNA double-strand breaks (DSB) at spe-
cific genomic sites, targeted by the sgRNA sequence [8,
9]. DSBs are repaired by the nonhomologous end-
joining (NHEJ) pathway generating short insertions and
deletions (indels), which ultimately may result in a loss-
of-function allele [8, 9].
Whole-genome screens by CRISPR-Cas9 can be de-
ployed in positive or negative selection settings. A posi-
tive selection screen allows for the identification of
genes whose knockout by sgRNAs gives a growth advan-
tage to a cell in a complex population (e.g. survival or se-
lectable phenotype). Genome-wide CRISPR-Cas9 screens
in a setting of positive selection have discovered gene mu-
tations that confer drug resistance, resistance to bacterial
toxins and genes involved in metastasis [1, 4, 5, 7, 10]. For
instance, using this approach Chen et al. discovered key
genes involved in early, late and metastatic cancer [1].
More specifically, they identified tumor suppressor genes
whose knockout by sgRNAs triggered cell proliferation
and increased metastasis formation. Contrarily, a negative
* Correspondence: Gerhard.rogler@usz.ch; Guglielmo.roma@novartis.com
†Equal contributors
1Department of Gastroenterology and Hepatology, University Hospital Zürich,
Zürich, Switzerland
2Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel,
Switzerland
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kiessling et al. BMC Genomics  (2016) 17:723 
DOI 10.1186/s12864-016-3042-2
selection or dropout screen can identify genes whose
knockout by sgRNAs cause the depletion of the cells.
In a setting of negative selection one aims to identify
oncogenic drivers, e.g. those genes that cause the for-
mation, or supports the progression, of a cancer.
While positive selection screens proved quite success-
ful so far, initial negative selection screens by CRISPR-
Cas9 detected many highly essential genes as screening
hits [1, 3, 5–7]. These genes are required for the pro-
liferation and survival of human cancer cell lines and
include factors for RNA transcription and DNA repli-
cation [1, 3, 5–7]. These studies also found many
previously uncharacterized genes involved in RNA
processing demonstrating that CRISPR-Cas9 screens
are a valid approach for the identification of genetic
dependencies [3, 6]. In an attempt to identify new
therapeutic targets, a recent negative selection study
focused on a few hundred chromatin regulatory genes
[11]. In this work the authors showed that CRISPR-
Cas9 mutagenesis directed to exons encoding func-
tionally important protein domains resulted in a higher
efficiency [11]. Several genes were found to be indis-
pensable for cell survival [11]. However, it is not
known whether other important fitness genes can be
identified besides the known oncogenes in EGFR and
NRAS mutant cells in a whole-genome CRISPR-Cas9
negative selection screen.
Using a genome-wide sgRNA library in two human
cancer cell lines with known mutations we show that
CRISPR-Cas9 dropout screens can differentiate onco-
genic drivers and pathways from the expected key sur-
vival genes. We exemplify this with the identification of
EGFR as one of the top hits in the EGFR mutated HCC-
827 line and NRAS and MAP2K1 (MEK1) among the
top hits in the NRAS mutated CHP-212 line. In
addition, we discover putative dependencies including
TBK1 and TRIB2. Our data show that whole genome
CRISPR dropout screens allow for the identification of
oncogenic drivers as well as essential genes for survival
that might be suitable for drug targeting.
Results
CRISPR-Cas9 screen and identification of essential genes
involved in fundamental cellular processes
To investigate whether pooled whole-genome CRISPR-
Cas9 screening is an appropriate means to identify onco-
genic drivers and novel dependencies we selected two
human cancer cell lines with known mutations: (1) the
neuroblastoma-derived cell line CHP-212, which carries
a RAS (NRAS) Q61K mutation and is highly sensitive to
MEK inhibitors [12, 13]; (2) the lung cancer cell line
HCC-827, which carries a deletion in the epidermal
growth factor receptor (EGFR) delE746 and is sensitive
to EGFR inhibitors including Gefitinib and Erlotinib
[14]. We introduced a human sgRNA library consisting
of 57 096 unique sgRNAs (3 sgRNAs/gene) and 1 000
non-targeting control sgRNAs [5] into CHP-212 and
HCC-827 cells by lentiviral transduction. Cells were then
grown under puromycin selection for 10 days, and gen-
omic DNA samples were collected at days 14, 21, and 28
thereafter without any selection pressure. Experiments
were conducted in duplicates (Fig. 1a).
Using deep sequencing we found that the diversity of
sgRNAs was reduced over time as expected (Fig. 1b, c,
Additional file 1: Figure S1a, b). The shift between con-
trol and days 14, 21 and 28 indicates the specific deple-
tion of sets of sgRNAs (Fig. 1b, c). Our data revealed
high coverage of the sgRNA library: at the control time
point 96.0 % of the sgRNAs were represented by at least
100 sequencing reads in HCC-827 and 98.9 % in CHP-
212 cells, respectively (Additional file 1: Figure S1a, b).
The percentage of sgRNAs detected significantly de-
creased after 14, 21, and 28 days as expected (Additional
file 1: Figure S1a, b). The obtained sgRNA representa-
tions showed high concordance between technical repli-
cates of CHP-212 cells (average correlation, ρ = 0.94)
and HCC-827 cells (average correlation, ρ = 0.92)
(Additional file 2: Table S1). High correlation was also
found between the controls of HCC-827 and CHP-212
cells (average correlation, ρ = 0.93), thus indicating
high reproducibility even between different biological
infections (Additional file 3: Table S2). Next, we calcu-
lated log2 fold changes by taking the logarithm of
sgRNA counts for one gene at each time point divided
by the average of the sgRNA counts of that gene at
the control time point (day −10). We found that the
overall technical variability across the screen was low
as the distribution of non-targeting versus targeting
sgRNAs was consistent across all time points within
each cell line (Fig. 1d, e). Variability was higher for the
CHP-212 than for the HCC-827 cell line (Fig. 1d, e).
Finally, principal components analysis (PCA) showed
that replicates at control time points cluster together
better than those at later time points (days 14, 21 and
28), thus suggesting that the variability between repli-
cates increases with time as response to the depletion
of the target genes (Additional file 1: Figure S2a, b).
All together these data indicate robustness of our
CRISPR-Cas9 screen based on high coverage of the
sgRNA library, low technical variability for the same
sgRNA across the different time points, and high
reproducibility between replicates across the whole
experiment. However, as previously described in [11,
15], we also observed variability between individual
sgRNAs targeting different loci of the same gene
(Additional file 1: Figure S3a, b). Thus, we decided
first to conduct further analyses at sgRNA level rather
than at gene level.
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Fig. 1 (See legend on next page.)
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We analyzed the sgRNA distributions to assess
whether perturbing gene function confers a growth ad-
vantage or disadvantage to the cells. Of the 57 096
unique sgRNAs used in the screen, we found a signifi-
cant portion leading to under-representation of the cells
at the different time points analyzed. Using gene set
enrichment analysis (GSEA) [16], we identified that
sgRNAs with decreased abundance in cells at day 14 tar-
get genes whose function is essential for cell survival
such as those involved in fundamental cellular processes
(e.g. cell cycle and mitosis, DNA replication, protein
translation, RNA splicing, non-sense mediated decay,
and RNA processing), key components of cellular organ-
elles (e.g. ribosomal, mitochondrial and nucleolar pro-
teins), as well as those encoding proteins with RNA and
poly(A)-RNA binding functions (Fig. 1f, g). These results
were confirmed at the later time points (data not
shown). Thus, our analysis indicates that loss-of-
function of these essential genes after 14 days of the
screen results in growth disadvantage to the cells from
both lineages.
Oncogenic driver mutations can be identified by
whole-genome CRISPR-Cas9 screen
To answer the question of whether a negative selection
CRISPR-Cas9 screen can identify genes playing a non-
redundant role in the oncogenic driver pathways, we de-
ployed two different approaches: (1) we analyzed fold
changes for all 57 096 sgRNAs; and (2) we focused on
the 1 751 sgRNAs which target kinases. Fold changes for
time points day 14, 21, and 28 were calculated as change
in frequency of the respective sgRNA compared to the
control time point at day −10. We compared fold
changes of all sgRNAs from day 14 versus day 21 and
found that most of the 1 000 non-targeting control
sgRNAs overlaid with the majority of all targeting
sgRNAs (Fig. 2a, b). This indicates that many data points
fall into the background variability of the CRISPR screen
(Fig. 2a, b). As a threshold level we used the fifth per-
centile of the fold changes of the depleted sgRNA (Fig. 2).
This includes 1 450 sgRNAs of all genes from a total of
57 096 sgRNAs (Fig. 2a) and 22 sgRNAs from kinase
sgRNAs (Fig. 2c) for the HCC-827 cell line. For the CHP-
212 cell line, 1 462 sgRNAs are among the 5 % most de-
pleted sgRNAs for all genes and 24 sgRNAs for kinases
(Fig. 2b, d). We provide the lists of 1 000 most depleted
genes for the HCC-827 and CHP-212 cell lines (Additional
files 4 and 5: Tables S3 and S4). We found EGFR scoring
high among the strongest depleted genes for the EGFR-
mutant HCC-827 cell line being well above the threshold
level (Fig. 2a). Similarly, NRAS and MAP2K1 – a kinase
downstream of NRAS [17] - were among the most depleted
genes for the NRAS-mutant cell line CHP-212 within the
threshold level (Fig. 2b). RAF1, another kinase downstream
of NRAS, was found to be below the threshold level
(Fig. 2b). These data show that oncogenic drivers and path-
ways can be differentiated from the multitude of key sur-
vival genes in our CRISPR-Cas9 screen, indicating that an
oncogenic driver mutation causes a strong dependency.
Then, we further examined the range of depleted
genes focusing our analysis on kinases, depicting the fold
changes of sgRNAs targeting kinases on days 14 and 21
(Fig. 2c, d). Again, we found EGFR and MAP2K1 among
the most depleted of all kinases (Fig. 2c, d); these genes
were identified at all time points, and confirmed by
replicates from the same time point (Additional file 1:
Figure S4a-f ). Of note, sgRNAs for MAP2K1, NRAS and
RAF1 were only depleted in CHP-212 cells but not in
HCC-827 cells excluding unspecific effects of the re-
spective sgRNAs (Additional file 1: Figure S4g). Simi-
larly, EGFR was depleted in the HCC-827 cell line but
not in the NRAS mutant CHP-212 cell line (Additional
file 1: Figure S4h). For each cell line, we report the lists
of the top 20 kinase-targeting sgRNAs with the strongest
depletion at each of the three time points analyzed
(Tables 1 and 2). EGFR was at the top position at all
three time points in the EGFR-mutant HCC-827 line
(Table 1). Similarly, MAP2K1 was among the top hits
for the NRAS-mutant CHP-212 line (Table 2). RNA-
sequencing of the parental HCC-827 and CHP-212 lines
confirmed that our top candidate genes were highly
expressed in the respective cells (Additional files 6
and 7: Tables S5 and S6). To determine potential off-target
effects of the sgRNAs we compared depletion of sgRNAs
(See figure on previous page.)
Fig. 1 Representation of whole genome sgRNA library at different time points. a Schematic representation of the negative loss-of-function screen
using lung cancer cell line HCC-827 and neuroblastoma cell line CHP-212. b Cumulative frequency of sgRNAs by deep sequencing at control time
point (day −10), day 14, day 21, and day 28 for HCC-827 cell line. Shift in the curves at days 14, 21, and 28 represents the depletion of essential
sgRNAs. Each time point was measured in duplicates. c Same as in b) but for CHP-212 cell line. d Plots of normalized sgRNA reads for HCC-827
cell line at time points day 14, day 21, and day 28. Dark colored dots represent the 1 000 non-targeting control sgRNAs and light colored dots
represent the 57 096 targeting sgRNAs. Each time point was measured in duplicates and log2 of median fold changes versus the control time
point (day −10) are represented. e Same as in d) but for CHP-212 cell line. f Gene ontology terms describing sgRNAs and genes whose knockdown
causes under-representation of HCC-827 cells at day 14. g Gene ontology terms describing sgRNAs and genes whose knockdown cause under-
representation of CHP-212 cells at day 14
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to the expression of the respective genes. We found that
less than 10 % of the top 5 % depleted genes are not
expressed in the HCC-827 cell line and <12.5 % for the
CHP-212 cell line (Figure S5a, b). This indicates that off-
target effects of the sgRNA library are in a lower range and
that 9 of 10 hits are likely valid candidates.
We observed that while some sgRNAs for a given gene
had a very strong effect on depletion others were mostly
ineffective (Figure S4g, h). This low sgRNA efficiency
has been also described by other studies and could be
due to several factors including the low expression of
Cas9, the non-optimal sequence of the sgRNA, a low
chromatin accessibility, and ultimately an insufficient
editing of the locus [15]. Thus, we decided to add an-
other analytical approach which encompasses all 3
sgRNAs. To compute a gene-based hit calling, we
applied a redundant siRNA activity (RSA) statistics [18]
on the fold changes obtained at day 14 versus the con-
trol time point (day −10). Our results confirmed the pre-
viously identified hits, EGFR, RAF1 and MAP2K1
among the very top hits in the plots for all sgRNAs and
for kinase sgRNAs only (Fig. 2e-h). Taken together, we
conclude that single sgRNA analysis and gene based
analysis of all 3 sgRNAs yield a comparable outcome.
Drug sensitivity to specific kinase inhibitors correlates
with sgRNA depletion of respective kinases
To validate the findings of the CRISPR-Cas9 screen, we
investigated the correlation between the sgRNA fold de-
pletion and the drug sensitivity of the cell lines. The
EGFR-mutant HCC-827 cell line was completely refrac-
tory towards MEK inhibition but highly sensitive to the
(See figure on previous page.)
Fig. 2 sgRNAs depleted in the whole genome screen. a Scatterplot representing fold changes of the 57 096 targeting sgRNAs in the HCC-827 cell
line at day 14 and day 21. Fold changes at day 14 or day 21 were calculated compared to the control time point at day −10. All time points were
measured in duplicates and median fold changes are shown. Dark green colored dots represent the 1 000 non-targeting control sgRNAs and grey
colored dots represent the 57 096 targeting sgRNAs. Genes of interest were annotated by the software Spotfire and visualization was further
enhanced by red colored dots. b Same as in a) but for CHP-212 cell line. c Scatterplot of fold changes of 1 571 kinases in the HCC-827 cell line at
time points day 14 and day 21 versus control time point day −10. d Same as c) but for HCC-827 cells. e, f Scatterplots for Q1 and RSA down of
57 096 targeting sgRNAs in the HCC-827 (e) and CHP-212 cell lines (f) at time point day 14. Dark green colored dots represent the 1 000
non-targeting control sgRNAs. g, h Scatterplot for Q1 and RSA down of the 1 571 sgRNAs for kinases are shown for the HCC-827 (e) and CHP-212
(f) cell lines
Table 1 List of top 20 sgRNAs targeting kinases for HCC-827 cells
Day 14 Day 21 Day 28
Kinase sgRNA Log2 fold change Kinase sgRNA Log2 fold change Kinase sgRNA Log2 fold change
EGFR HGLibA_14637 −5.61 EGFR HGLibA_14637 −4.88 EGFR HGLibA_14637 −5.49
NRBP1 HGLibA_39943 −5.37 CHEK1 HGLibA_09418 −4.81 NRBP1 HGLibA_39943 −5.37
TP53RK HGLibA_58364 −5.08 LTK HGLibA_34898 −3.67 PDPK1 HGLibA_43219 −4.54
RIPK2 HGLibA_48607 −4.64 SRPK2 HGLibA_54308 −3.45 CDK11A HGLibA_08724 −3.98
CHEK1 HGLibA_09418 −4.58 CDK11A HGLibA_08724 −3.39 TBK1 HGLibA_55891 −3.78
PIK3R3 HGLibA_43942 −4.54 WEE1 HGLibA_61525 −3.22 CHEK1 HGLibA_09418 −3.57
WEE1 HGLibA_61525 −4.10 RET HGLibA_48160 −3.17 WEE1 HGLibA_61525 −3.48
TBK1 HGLibA_55891 −4.06 TBK1 HGLibA_55891 −3.00 CDK2 HGLibA_08756 −3.37
DYRK2 HGLibA_14277 −3.96 NRBP1 HGLibA_39943 −2.88 TP53RK HGLibA_58364 −2.97
MERTK HGLibA_36194 −3.78 PHKG1 HGLibA_43699 −2.64 TLK1 HGLibA_56909 −2.82
CLK2 HGLibA_10058 −3.49 TP53RK HGLibA_58364 −2.48 RET HGLibA_48160 −2.81
PKMYT1 HGLibA_44123 −3.41 PDPK1 HGLibA_43219 −2.47 PKMYT1 HGLibA_44123 −2.80
CDK11A HGLibA_08726 −3.40 PRKAA1 HGLibA_45780 −2.43 MUSK HGLibA_37865 −2.73
PDPK1 HGLibA_43219 −3.36 SCYL1 HGLibA_50372 −2.32 PHKG1 HGLibA_43699 −2.72
IKBKE HGLibA_30211 −3.30 PKMYT1 HGLibA_44123 −2.31 PIK3R3 HGLibA_43942 −2.67
CSNK1D HGLibA_11388 −3.28 PRKCD HGLibA_45826 −2.29 DYRK2 HGLibA_14277 −2.62
CDK11B HGLibA_08729 −3.21 TBK1 HGLibA_55890 −2.27 TBK1 HGLibA_55889 −2.52
CDK4 HGLibA_08771 −3.17 CDK12 HGLibA_08731 −2.25 PAK4 HGLibA_42338 −2.46
AURKA HGLibA_03873 −3.14 CLK2 HGLibA_10058 −2.25 RIPK2 HGLibA_48607 −2.44
LTK HGLibA_34900 −3.02 CDK2 HGLibA_08756 −2.22 PRKAA1 HGLibA_45780 −2.43
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EGFR inhibitor Gefitinib [13, 14] (Fig. 3a, left panel). In
contrast, the NRAS-mutant cell line CHP-212 was
highly sensitive towards MEK inhibition but insensitive
towards Gefitinib (Fig. 3b, left panel). As expected, the
drug sensitivity of the two cell lines broadly agreed with
the sgRNA-based depletion of these genes observed in
the screen (Fig. 3a, b, middle panel). We found that the
fold changes of sgRNAs strongly correlated with sensi-
tivity towards respective inhibitors of the target (correl-
ation ρ = 0,99). These results were corroborated by the
other MEK inhibitor MEK162 and the EGFR inhibitor
Erlotinib (Additional file 1: Figure S6). In conclusion,
our data show that sgRNA depletion strongly correlates
with sensitivity to respective kinase inhibitors of the as-
sociated pathways in cell viability assays.
In another approach, we wanted to validate novel hits
from the candidate list for which kinase inhibitors are
available. For instance CHEK1 was a hit in both cell
lines (Tables 1 and 2). Thus, we were curious to investi-
gate the effect of the CHEK1 inhibitor AZD7762 on cell
viability. Indeed, the CHEK1 inhibitor AZD7762 strongly
blocked cell viability in both cell lines with EC50 values
for CHP-212 and HCC-827, respectively (Fig. 4a). In
addition, members of the cyclin dependent kinase
(CDK) family were also abundant among the candidate
list of our screen in both cell lines represented by
depletion of CDK2, CDK4, CLK2, CDC7 and CDK11A,B
(Tables 1 and 2). Indeed, depletion of the CDK2 and
CDK5 correlated with sensitivity towards the CDK in-
hibitor CGP60474 for HCC-827 cells and for CHP-212
cells (Fig. 4b). Of note, for both CHEK1 and CDK2/5
most sgRNAs resulted in a strong depletion of genes
from the screen (Fig. 4a, b: middle panels). As a control,
we thought to determine kinases whose sgRNA counts
were found to be stable or increased throughout the
screen (Fig. 4c-e: middle panel) and for which kinase in-
hibitors are available. We found that sgRNAs for AKT1/
2/3, FGFR1/2/3, and A- or BRAF inhibitors did not
change significantly throughout the screen in both cell
lines (Fig. 4c-e, right panel). As expected, inhibitors
against these kinases had no effect on cell viability in
both cell lines (Fig. 4c-e, left panel). Taken together,
these data show that depletion of sgRNAs indicated sen-
sitivity towards inhibitors of the respective target genes
and that cell lines are highly sensitive to inhibitors of
top ranking kinases from our screen.
Identification of putative novel dependencies TBK1 and
TRIB2
Finally, we wanted to describe unexpected dependencies
in these cell lines. The tank-binding kinase TBK1 was
among the strongest hits identified by the two different
Table 2 List of top 20 sgRNAs targeting kinases for CHP-212 cells
Day 14 Day 21 Day 28
Kinase sgRNA Log2 fold change Kinase sgRNA Log2 fold change Kinase sgRNA Log2 fold change
TRIB2 HGLibA_58681 −5.96 STRADA HGLibA_54860 −6.17 CLK2 HGLibA_10058 −5.49
STRADA HGLibA_54860 −5.41 CDC7 HGLibA_08595 −6.09 CHEK1 HGLibA_09420 −5.37
BRD2 HGLibA_04772 −5.31 TRIB2 HGLibA_58681 −6.06 RIOK2 HGLibA_48597 −4.54
TEX14 HGLibA_56351 −5.14 PDK1 HGLibA_43184 −5.65 MAP2K1 HGLibA_35426 −3.98
MAP2K6 HGLibA_35443 −4.83 VRK1 HGLibA_61113 −5.64 GAK HGLibA_18491 −3.78
CDC7 HGLibA_08595 −4.77 RIOK2 HGLibA_48597 −5.27 AATK HGLibA_00089 −3.57
VRK1 HGLibA_61113 −4.75 BRD2 HGLibA_04772 −5.21 ACTR2 HGLibA_00655 −3.48
PDK1 HGLibA_43184 −4.59 TEX14 HGLibA_56351 −5.14 TP53RK HGLibA_58364 −3.37
RPS6KB1 HGLibA_49465 −4.58 YES1 HGLibA_61950 −5.11 BRD2 HGLibA_04772 −2.97
ZAP70 HGLibA_62062 −4.57 GAK HGLibA_18491 −5.02 PDK1 HGLibA_43184 −2.82
MAP2K1 HGLibA_35426 −4.52 PTK2 HGLibA_46667 −4.89 BRD2 HGLibA_04773 −2.81
RAF1 HGLibA_47416 −4.37 CHEK1 HGLibA_09418 −4.88 TRIB2 HGLibA_58681 −2.80
KIT HGLibA_32303 −4.36 RIPK1 HGLibA_48603 −4.88 YES1 HGLibA_61950 −2.73
RIOK2 HGLibA_48597 −4.35 CHEK1 HGLibA_09420 −4.86 CDC7 HGLibA_08595 −2.72
SBK2 HGLibA_50091 −4.33 ZAP70 HGLibA_62062 −4.71 VRK1 HGLibA_61113 −2.67
GAK HGLibA_18491 −4.32 RPS6KB1 HGLibA_49465 −4.70 STK38L HGLibA_54791 −2.62
SYK HGLibA_55237 −4.21 MAP2K1 HGLibA_35426 −4.60 SBK2 HGLibA_50091 −2.52
PTK6 HGLibA_46673 −4.11 MAP2K6 HGLibA_35443 −4.59 PKMYT1 HGLibA_44123 −2.46
RIOK1 HGLibA_48595 −3.98 KIT HGLibA_32303 −4.57 NEK1 HGLibA_38926 −2.44
IGF1R HGLibA_30081 −3.92 RPS6KA4 HGLibA_49455 −4.53 CDK11A HGLibA_08726 −2.43
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analysis approaches in the HCC-827 cell line (Fig. 5a, b).
TBK1 was at position 5 in the sgRNA-based analysis and
at position 1 in the gene-based analysis (Fig. 5a). TBK1
was described as co-synthetic lethal in KRAS mutant
lung cancer [19] but, so far, it has not been associated
with EGFR mutant cancer. We found that sgRNAs tar-
geting TBK1 decrease cell viability for HCC-827 (Fig. 5b).
Efficacy for knock-out of different sgRNA correlated
with the degree of decrease of cell viability (Fig. 5b). In
addition, in a colony formation assay, knock-down of
TBK1 by different sgRNAs significantly reduced ability
of cells to form colonies (Fig. 5c). TBK1 shows a strong
expression in the HCC-827 cell line similarly to EGFR
(Additional file 6: Table S5). We observed that many po-
tential hits are strongly expressed (Additional file 6:
Table S5). Two recent studies observed that CRISPR/
Cas9 screens may generate false-positive hits for genes
with high copy numbers or genes in amplified regions
[20, 21]. The authors describe that DNA breaks by
CRISPR/Cas9 in amplified regions cause an antiprolifer-
ative effect independent of the respective gene targeted
by the sgRNA [20]. Using the canSAR database [22], we
indeed found that TBK1 has 10 copy number variants in
the parental HCC-827 cell line. While further studies are
needed to prove that TBK1 is a true dependency, we can
conclude that these experimental data validate the find-
ings of our CRISPR screen.
In addition, we validated another hit for the CHP-212
cell line. We found that tribbles pseudokinase 2 (TRIB2)
was scoring high in both analyses (Fig. 5d). 5 different
sgRNAs, 4 of which newly designed for the targeted val-
idation, reduced cell viability compared to a non-
targeting control for TRIB2 (Fig. 5e). Again, these results
demonstrate the high reproducibility of the screen. A
search in the canSAR database [22] showed that TRIB2
has 14 different copies in the CHP-212 cell line and we
conclude that further studies are needed to validate
TRIB2. The role of TRIB2 in cancer and its potential
druggability merit further investigations.
Discussion
Here, we found that screening with a commercially
available CRISPR-Cas9 library enables the identification
of oncogenic driver mutations and the discovery of novel
putative therapeutic targets. We show that relevant
druggable targets can be identified through a whole-
genome approach with known massive depletion of
genes involved in basic cellular functions including cell
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Fig. 3 Depletion of kinases EGFR and MAP2K1 correlates with sensitivity towards EGFR and MEK inhibitors. a left panel: HCC-827 and CHP-212 cells
were treated with indicated concentrations of Gefitinib for 72 h. Then, cell viability was measured by Cell Titer Glo according to the manufacturer’s
instructions. Middle panel: Fold change for the three independent sgRNAs for EGFR from the screen are depicted at time point day 14. Right panel:
HCC-827 and CHP-212 cells were treated for 2 h with the indicated concentrations of Gefitinib. Then, cells were lysed and analysed by Western blot.
b same as a) but the MEK inhibitor AZD6244 was used instead (left panel) and fold change for sgRNAs for MAP2K1 and MAP2K3 from the screen are
depicted (middle panel). Right panel: HCC-827 and CHP-212 cells were treated for 2 h with the indicated concentrations of AZD6244. Then, cells were
lysed and analysed by Western blot
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transcription and replication. We chose two human can-
cer cell lines with known mutations: EGFR mutations
are found in 10–15 % of lung cancer patients. NRAS
mutations activate downstream kinases including RAF
and MEK1/2 (MAP2K1/2) [17], and preclinical and early
clinical data showed that NRAS-mutant cell lines and
tumors of cancer patients are highly sensitive to MEK1/
2 inhibitors [13, 23]. SgRNAs targeting the two driver
mutations, used as intrinsic controls for our screen,
showed up in the top-candidate list. SgRNAs targeting
the driver mutations could be identified at days 14, 21
and 28 indicating that knock-out efficiency at day 14 suf-
fices. We noticed that EGFR ranked higher for the
HCC-827 cell line than MAP2K1 for the CHP-212 cell
line. This is consistent with the fact that we found more
background noise in the CHP-212 line as indicated by
the higher variability of non-targeting controls. Whether
this is specific to CHP-212 cells or might occur also in
other cell lines has to be investigated by further
CRISPR-Cas9 screens in more cell lines. Nevertheless,
focusing the analysis on kinases revealed the repetitive
appearance of MAP2K1 and RAF1 among the most de-
pleted kinases at most time points (Table 2). This indi-
cates that the hyperactivity of the RAS pathway due to
the NRAS mutations is presented by the identification of
the respective downstream kinases.
Further, we found that the expected hits from the
CRISPR screen are strongly expressed (Fig. 2, Additional
file 1: Figure S5). This is interesting, since RNA sequen-
cing and expression may help to identify genes which
are not expressed and therefore delineate potential
CRISPR off-target effects. In our data we estimated the
sgRNA off-target effect to be below 10 % and 12.5 % for
HCC-827 cells and CHP-212 cells, respectively. This
would imply that at least 8 or 9 out of 10 hits could be
true hits that may be valid for further investigations.
Besides the expected targets EGFR and MAP2K1, our
screen revealed also other putative drug targets that
showed strong depletion. For example, we found TBK1,
a kinase so far associated with KRAS mutations, as a top
hit in HCC-827 cells (Fig. 5). TBK1 was shown to be co-
lethal in KRAS mutant lung cancer and it has been in-
vestigated as a potential target in triple-negative breast
cancer [19, 24]. Whether TBK1 plays a role in EGFR
mutant lung cancer is currently not known. For CHP-
212 we were able to validate the screening results for the
cell cycle kinase TRIB2 (Fig. 5). We took advantage of
the three recent studies published [3, 6, 25] to check
whether the genes described in our work were reported
to be “essential genes” in previous screens (Additional
file 1: Figures S3 and S4). We can confirm that TBK1
and TRIB2 are not present in any of the three published
lists of essential genes [3]. The finding of these kinases is
highly interesting and especially their role in cancer is
poorly understood. However, it has to be taken into con-
sideration that CRISPR-Cas9 may generate false-positive
hits since genes with high copy numbers or areas with
amplified regions are especially sensitive to DSB by Cas9
[20, 21]. Thus, identified potential hits need further con-
firmation by shRNA experiments and studies on more
cell lines. The hypothesis that these kinases might be
suitable co-drug targets for treatment of cancer patients
merits further investigations.
Currently, it is speculated whether the diploid or poly-
ploid genome of mammalian cells would be an obstacle
for whole-genome CRISPR-Cas9 screening [26]. The cell
line CHP-212 was found to be diploid whereas the
HCC-827 cells are tri- to hexaploid (Additional file 1:
Figure S7). This indicates that chromosomal aberrations
are not necessarily a barrier for the identification of
driver mutations.
The outcome and strength of CRISPR-Cas9-mediated
genetic screening in general, and for loss-of-function
dropout screen in particular, is dependent on the effi-
ciency of gene knockout. Gene knockout efficiency is in-
fluenced by the expression levels of Cas9, the sequence
of the sgRNA [11], and the chromosomal context [11].
Recently, it was found that knock-out of genes is more
efficient if Cas9 is directed to highly conserved, func-
tional domains [11]. In this work we confirm that
sgRNAs targeting different exons of the same gene can
lead to different efficiency in the phenotype. This out-
come confirms previous data showing that independent
sgRNAs can give high variability in the phenotype pene-
trance [1, 10, 11]. We also observed high variability of
sgRNAs targeting the same gene. For example, one
sgRNA targeting EGFR scored extremely high while the
two others remain ineffective (Additional file 1: Figure
S4g). The reason for the different sgRNA efficacy could
not be studied further here. However, we could show
that both analytic approaches, e.g. 1) focusing on fold
change of single sgRNAs and 2) combining all 3 sgRNAs
per gene, yield reliable results (Fig. 2). However, we con-
clude that analyzing individual sgRNAs is superior and
(See figure on previous page.)
Fig. 4 Validation of target kinases by inhibitors. a left panel: HCC-827 and CHP-212 cells were treated with indicated concentrations of CHEK1
inhibitor AZD7762 for 72 h. Then, cell viability was measured by Cell Titer Glo according to the manufacturer’s instructions. Middle panel: Fold
changes for three independent sgRNAs for CHEK1 inhibitor AZD7762 are depicted at time point day 14. b Same as a) but CDK1,2,5,7,9 inhibitor
and respective sgRNAs are shown. c Same as a) but AKT1/2/inhibitor MK2206 and respective sgRNAs are shown. d Same as a) but FGFR inhibitor
BGJ398 and respective sgRNAs are shown. e Same as a) but BRAF inhibitor Vemurafenib and respective sgRNAs are shown
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Fig. 5 (See legend on next page.)
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more reliable since EGFR - a well-studied and defined
oncogene which is highly relevant as a predictive marker
for treatment of lung cancer patients - showed a score
higher in single sgRNA analysis than in the combined
sgRNA setting (Fig. 2). In conclusion, screening with
more sgRNAs per gene might increase robustness of the
screening. Thus, 2nd and 3rd generation CRISPR/Cas9
sgRNA libraries designed with novel prediction algo-
rithms might overcome these limitations. Further, the in-
tegration of hits generated from CRISPR screens in
other cancer cell lines might help filter out pan-lethal
targets and highlight important unknown dependencies.
In fact if we disregard from our analysis those genes
found to be essential in recent papers [3, 6] and those
that score in both our cell lines, EGFR and NRAS rank
respectively 2nd and 7th based on their cumulative
screening score (e.g. the cumulative log fold changes at all
three time points) and their expression level (Additional
files 8 and 9: Tables S7 and S8).
For our screen, we have observed that 3 independent
sgRNAs were sufficient to identify known oncogenes
and novel dependencies. However, we cannot exclude
that targets were missed because all 3 sgRNAs for a sin-
gle gene were ineffective in inducing a phenotypically
relevant knockout.
Conclusions
In summary, we found that oncogenic driver mutations
and target kinases can be identified by a whole-genome
CRISPR-Cas9 dropout screen. CRISPR-Cas9 screening
supports the discovery of novel drug targets.
Methods
Chemicals
AZD6244, MEK162 and Erlotinib were purchased from
Selleck Chemical. Gefitinib were kindly provided by
Viktoras Frismantas and Jean-Pierre Bourquin, Childrens
University Hospital Zurich. All inhibitors were solubi-
lized in dimethyl sulfoxide (DMSO) at stock concentra-
tions of 10 mM.
Cell culture
CHP-212 and HCC-827 cells were purchased from
ATCC. CHP-212 cells were cultured in DMEM and F12
medium (1:1) supplemented with 10 % fetal calf serum
(FCS) and 1 mM L-glutamine. HCC-827 cells were cul-
tured in RPMI-1640 supplemented with 10 % FCS.
Karyotyping of cell lines
A T25 cell culture flask with 5 ml media and approxi-
mately 60 % confluence was obtained for each sample.
Cultures were incubated with 25 μl colcemid (Karyo-
MAX Colcemid Solution, 10 μg/μl; Life Technologies,
Zug, Switzerland) at 37 °C and 5 % CO2 for 24 h before
harvest. Chromosome preparation was done using
standard techniques [27]. Briefly, the adherent cells were
detached using incubation with trypsin, followed by
hypotonic treatment, fixation with methanol-acetic acid,
slide preparation and GTG banding. Metaphases were
searched and captured using an automated microscope
equipped with a scanning software (Metafer, MetaSys-
tems GmbH, Altlussheim, Germany). Metaphases were
analyzed using the Metasystems IKAROS software.
Lentivirus production and purification
GeCKO Library A was purchased from Addgene and li-
brary was purified according to manufacturer’s instruc-
tions. For lentivirus production, 30 T-75 flasks with
HEK293T cells were seeded to reach 70–80 % conflu-
ence the day of transfection in DMEM supplemented
with 10 % fetal bovine serum. 30 min prior to transfec-
tion, media was removed and fresh prewarmed media
with 25 μM chloroquine was added. Transfection was
performed using the CaCl2 method (https://web.stanfor-
d.edu/group/nolan). 20 ug of lentiCRISPR plasmid li-
brary, 10 ug of pVSVg, and 15 ug of psPAX2 (Addgene)
were mixed with 61ul of 2M CaCl2, then 459ul of
ddH2O was added, finally 500ul of 2xHBS (Na2HPO4
dibasic (5.25 g in 500 ml of water), 8.0 g NaCl 6.5 g
HEPES (sodium salt) 10 ml Na2HPO4 stock solution,
pH to 7.0 using NaOH or HCl) were added. Then, 2 ml
of the DNA-Ca precipitate are added to each flask. After
12 h, the media was removed and fresh DMEM +10 %
FCS media was added. After 48–72 h, the media was
pooled and centrifuged at 3,000 rpm at 4 °C for 5 min
twice to pellet cell debris. Then, the supernatant was
ultracentrifuged at 25,000 rpm for 2 h at 4 °C (Sorvall)
(See figure on previous page.)
Fig. 5 Validation of the screen by knock-out of TBK1 and TRIB2. a Left side: Scatterplot of fold changes for the 1 462 kinase sgRNAs of the
HCC-827 cell line at time point day 14 and time point day 21 versus control time point day −10. sgRNAs against TBK1 were annotated by the
software Spotfire and visualization was further enhanced by red colored dots. Rigth side: Scatterplot of Q1 and RSA down for the 1 462 kinase
sgRNAs of the HCC-827 cell line at time point day 14 versus control time point day −10. b HCC-827 cell line was transduced with a non-targeting
sgRNA against GFP and 5 different sgRNAs against TBK1 (TBK1_2 is a sgRNA included in the genome-wide screens while the other 4 were newly
designed for this validation). Cell viability was measured 18days after viral transduction. c Equal number of cells transduced with a non-targeting
sgRNA against GFP and 5 different sgRNAs against TBK1. Crystal violet staining was performed after 28 days. d-e Same as in a-c but CHP212 cells
were used with the candidate TRIB2
Kiessling et al. BMC Genomics  (2016) 17:723 Page 12 of 16
and then suspended overnight at 4 °C in 1 ml OPTI-
MEM. Aliquots were stored at −80 °C.
Large scale spin transduction
Cells were transduced virally with the sgRNA library by
spinfection. Multiplicity of infection (MOI) was deter-
mined prior by infecting target cells with 1, 5, 10, 25,
50 μl of ultracentrifuged viral supernatant and selection
with puromycin 48 h after viral transduction (the opti-
mal puromycin concentrations were analyzed separately,
1ug/μl was found to kill 100 % of CHP-212 whereas
HCC-827 required 4ug/μl), then viability was measured
by cell titer glo 96 h after addition of puromycin. We
aimed to cover each sgRNA by at least 100 reads for the
control time point, resulting in 100 × 57 096 sgRNAs
(=5.71 × 106 cells). Assuming a MOI of 0.5 to ensure
proper representation of the library and considering that
50 % are taken out of the pool at day 3 at least 4 ×
5.71 × 106 would be required. Finally, large-scale spinfec-
tion of 30 × 106 cells (CHP-212 and HCC-827) was car-
ried out with calculated volume of purified virus
according to MOI of 0.5 in 24-well plates which resulted
in coverage of 100 reads for >96 % of all sgRNAs and
200 reads for >95 % of all sgRNAs in both cell lines for
the control time point (Fig. 1b, c). Standard media for
each cell line (see Cell culture) for spinfection was sup-
plemented with 8 ug/ml polybrene (Sigma). The 24-well
plate was centrifuged at 2,250 rpm for 2 h at 24 °C. Im-
mediately after the spin, old media was carefully aspi-
rated and fresh media without polybrene was added to
the cells.
Depletion screen
On day 3, 50 % of cells were harvested for the baseline
time point (control time point). Then, 4 μg/ul or 1 μg/μl
of puromycin (0.5 μg/mL) was added to HCC-827 and
CHP-212 cells for 10 days, respectively. On day 10,
media was removed and fresh media without puromycin
added. HCC-827 and CHP-212 were split every 3–4 days
once confluence reached 70 - 80 %. After 14, 21, and
28 days, at least 30 × 106 cells were harvested in dupli-
cates for genomic DNA extraction and analysis.
Genomic DNA sequencing
Extraction of DNA and further sample preparation was
done as described previously by Shalem O. et al. [5].
Harvested cell pellets were thawed and genomic DNA
was isolated with a Blood & Cell Culture Maxi kit (Qia-
gen). The PCRs for amplification of the library were per-
formed in two steps [5]. First, sgRNAs were amplified
from genomic DNA. According to [5], an input amount
of 130 ug genomic DNA was used for 12 separate PCR
reactions in 100ul using Herculase II Fusion DNA Poly-
merase (Agilent) to achieve 300X coverage over the
sgRNA library (assuming 6.6 ug of gDNA for 10 [6]
cells). The 12 generated PCR amplicons were then
pooled. Amplification was carried out with 18 cycles for
the first PCR. Primer sequences to amplify sgRNAs from
genomic DNA are:
F1 AATGGACTATCATATGCTTACCGTAACTTGAA
AGTATTTCG
R1 CTTTAGTTTGTATGTCTGTTGCTATTATGTCT
ACTATTCTTTCC
Second, another PCR was performed to attach Illu-
mina adaptors and to barcode samples. This second
PCR was done using 5ul of the product from the first
PCR in 10 replicates in a reaction volume of 100 ul [5].
Primers for the second PCR contained in the forward
primer a staggered length sequence to increase complex-
ity of the library and an 8 bp barcode for multiplexing
the different biological samples:
F2 AATGATACGGCGACCACCGAGATCTACACTCT
TTCCCTACACGACGCTCTTCCGATCT
(1–9 bp variable length sequence) (8 bp barcode)tcttgtg
gaaaggacgaaacaccg
R2 CAAGCAGAAGACGGCATACGAGATGTGACTG
GAGTTCAGACGTGTGCTCTTCCGATCT
tctactattctttcccctgcactgt
Amplification for the second PCR was done with 16 cy-
cles (HCC-827) and 20 cycles (CHP-212). The amplicons
from the second PCR were pooled and gel extracted. Se-
quencing was done with a HiSeq 2500 (Illumina). The
raw sequencing reads are available in the NCBI Short
Read Archive under the accession number SRP062971.
Data processing and primary analysis
The reads of the raw FASTQ files were aligned against
the FASTA file containing the designed sgRNA se-
quences from the library using the local alignment mode
of the Bowtie2 aligner [28] allowing for one mismatch.
After alignment, the number of aligned reads for each
sgRNA sequence was calculated and normalized to the
75 percentile of the mean of the samples in the data set
[29]. In order to deal with zero count sgRNAs in the
computation of fold changes, a pseudo-count of 0.1
CPM was added to the normalized counts. After aver-
aging the sgRNA values over the two replicates for each
time point, we computed the log2 fold changes by divid-
ing by the average of the baseline samples at the control
time point (day −10) and then taking the base 2 loga-
rithm. We calculated a cut-off for potential hits by con-
sidering only the 5 % most depleted sgRNAs from all
depleted sgRNAs in a cell line. For the cell line HCC-
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827 at time point day 14, the 5 % threshold includes 1
450 sgRNAs for all genes or 22 sgRNAs for kinases from
a total of 57 096 sgRNAs. This equals a fold change of <
−2,66 for time point 14 and of < −1,8 for time point day
21. For CHP-212 cells, we calculated a cut-off at −3,6 for
time point day 14 and −4,15 for time point day 21 ac-
cordingly. This includes 1 462 sgRNAs for all genes and
24 sgRNAs for kinases for the CHP-212 cell line at time
point day 14.
Kinases in our screen were identified by using previ-
ously published data of all putative kinases found in the
human genome [30]. Ranking of kinases was done ac-
cording to calculated log2 fold changes. We also com-
puted RSA scores as previously described in [18] using
the log2 fold changes obtained at day 14 versus the con-
trol time point (day −10), as well as the Q1 (1st quartile)
scores which are given as the mean of the lowest and
second lowest sgRNA value of the three sgRNA values
for a gene. Candidate genes were obtained by ranking
their RSA-down score in ascending order.
Gene set enrichment analysis
Gene set enrichment analyses were run using a custom
Python script that performs standard one-tailed
Kolmogorov-Smirnov tests [16] on the log2 fold ratios
between the first time point T1 (Day 14) and the con-
trol T0 (Day −10). For each gene and each time point,
we chose the log2 fold ratio that is maximal in terms of
absolute values for sgRNAs targeting the same gene. As
gene sets we used GO Biological Processes, GO Mo-
lecular Functions as well as GO Cellular Components
and allowed for gene set sizes between 20 and 2000.
Altogether we tested 1747 gene sets. We ranked the
gene sets according to the significance values (negative
log10 p-values) of the two one-tailed Kolmogorov-
Smirnov tests for positive and negative fold changes
and selected the top 20 gene sets (if any) above a
threshold of 7 for the negative log10 p-value. p-values
were multi-experiment adjusted using the Benjamini-
Hochberg method. In order to assess the robustness of
our analysis, we performed additional enrichment ana-
lysis with different test statistics and multi-experiment
corrections and obtained very similar results (not
shown).
RNA sequencing
Total RNA was isolated in triplicates from CHP-212 and
HCC-827 cells using the RNeasy Mini isolation kit in-
cluding on-column DNase digestion according to the
manufacturer’s instructions (Qiagen). RNA quality was
assessed with the RNA 6000 Nano Kit (Agilent). RNA-
seq libraries were prepared using the TruSeq Stranded
mRNA Sample Prep kit v2 (Illumina) and sequenced in
strand specific paired-end mode, 2x76bp, using the
HiSeq2500 platform. Read quality was assessed by run-
ning FastQC (version 0.10) on the FASTQ files. Sequen-
cing reads showed high quality, with a mean Phred score
higher than 30 for all base positions. A total of 453 bil-
lion 76-base-pair (bp) paired-end reads was mapped to
the human reference genome (hg38) and the human
gene transcripts from Ensembl v76 [31] by using an in-
house gene quantification pipeline [32]. On average,
more than 97 % of the total reads were mapped to the
genome or the transcripts, and more than 91 % to the
exons and junctions (expressed reads). Genome and
transcript alignments were used to calculate gene counts
based on Ensembl gene IDs. The raw RNA-sequencing
reads are available in the NCBI Short Read Archive
under the accession number SRP062973.
Western blot analysis
A total of 5 × 105 cells were lysed for 30 min in ice-
cold MPERM buffer supplemented with 25 mM NaF,
1 mM dithiothreitol, and complete protease inhibitor
cocktail from Roche Diagnostics. Equal amounts of
protein were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis. Then, separated
proteins were blotted onto a nitrocellulose membrane
(GE Healthcare) followed by blocking with 5 % bovine
serum albumin in phosphate-buffered saline/Tween
(0.05 % Tween-20 in phosphate-buffered saline). The
following antibodies were used: anti-phospho-ERK (P-
p44/p42 (Tyr202/204, #9101, Cell Signaling Technol-
ogy), anti-ERK (p44/p42, # 4695, Cell Signaling Technol-
ogy), anti-phospho MEK (Ser298, #9128, Cell Signaling
Technology), anti-MEK (# 8727, Cell Signaling Technol-
ogy), anti-TBK1 (Cell Signaling Technology), and anti–
tubulin (Sigma-Aldrich).
Cell proliferation and viability assays
Cell proliferation was measured with the Cell-Titer-Glo
Reagent (Promega) according to manufacturer’s instruc-
tions. Cells were plated in clear-bottomed 96-well plates
at a density of 500–2500 cells per well. The next day,
drugs were added at indicated concentrations and cell
proliferation was measured 4 days later. Proliferation
measurements were made using a standard 96-well plate
luminometer/plate reader (Synergy 2, Biotek). Data are
shown as relative values in which the luminescence at a
given drug concentration is compared with that of un-
treated cells of the same type. All experimental points
were set up in duplicate and were conducted at least 3
independent times. IC50 were calculated with GraphPad
Prims. Correlation of fold changes of sgRNA downregu-
lation and effect of drug treatment was calculated com-
paring the fold changes in sgRNAs with decrease in cell
viability after drug treatment in Excel.
Kiessling et al. BMC Genomics  (2016) 17:723 Page 14 of 16
Cloning of individual sgRNAs
sgRNAs for TBK1 and TRIB2 were designed by the
sgRNA designer from the Broad Institute (http://
www.broadinstitute.org/rnai/public/analysis-tools/sgrna-
design). sgRNAs were then cloned into target vector
lentiCRISPR_v2 (Addgene, Plasmid #52961) according
to manufacturer’s instructions. sgRNAs for TBK1 include:
TBK1_2 also used in the screen (CATAAGCTTCCT
TCGTCCAG); TBK1_3 (CCTGAGTCTCGAGGAGGC
CG); TBK1_4 (TCCACGTTATGATTTAGACG); TBK1_5
(ACATTTCCCTAAAACTACTG); TBK1_6 (GACAGCA
GATTATCTCCAGG). sgRNAs for TRIB2 include:
TRIB2_1 also used in the screen (AGAGTTTCAGCCC
GAACCT); TRIB2_2 (TTAACTGAGCTCATGCCCCA);
TRIB2_3 (CTATTAATACCGCCTCGCCG); TRIB2_4
(CCTTGTCTCCTGGTTACGAA); TRIB2_5 (AGCCT
GTGCTGACCTCCGCG); TRIB2_6 (GCTGCCCTAT
TCACTTCTAA). Viruses were generated and transduced
as described above. Transduced cells were rested for
2 days, then puromycin was added for 2 days. Next, cells
were seeded for cell viability or clonogenicity assays.
Additional files
Additional file 1: Supplementary Figures. Figure S1. Coverage of the
sgRNA library in HCC-827 and CHP-212 cells. a) Coverage of the sgRNA
library by deep sequencing at indicated time points for the HCC-827 cell
line. Each time point was measured in duplicates and average percentages
are represented here. b) Same as in a) but CHP-212 cell line is used instead.
Figure S2. Principal Components Analysis (PCA) plots for different time
points in HCC-827 and CHP-212 cells. PCA plots representing the sgRNA
counts obtained for both cell lines. Figure S3. Histogram plots of the difference
between the maximum and the minimum sgRNA fold changes per
gene. These histogram plots show the variability among sgRNAs
targeting the same gene calculated as the delta between the
maximum and the minimum sgRNA fold changes for each gene for
the HCC-827 and the CHP-212 cell lines on day 14. Figure S4.
Depleted sgRNAs for kinases in HCC-827 and CHP-212 cells. Time
points were measured in duplicates and median fold changes are
represented here. Dark green colored dots represent the 1 000 non-
targeting control sgRNAs and grey colored dots represent the 57 096
targeting sgRNAs. a-d) Scatter plots of fold changes compared to the
control time point are shown for the HCC-827 and the CHP-212 cell
line. f,g) Scatter plots of fold changes of 57 096 targeting sgRNAs of
the HCC-827 and CHP-212 cell lines at indicated time points. e, f)
Scatter plot of fold changes for independent replicates at time point
day 14 for HCC-827 (S4e) and CHP-212 (S4f), respectively. g,h) Scatter
plots of fold changes of 57 096 targeting sgRNAs of the HCC-827
and CHP-212 cell lines at indicated time points. Figure S5. Estimation of off-
target effects. a) Scatter plots of mRNA expression levels expressed in FPKMs
were compared to depletion by Q1 for the HCC-827 cell line. Of the 5 %
most depleted genes which is equal to 1 450 sgRNAs, more than 90 % were
expressed with a FPKM> 1. b) Of the 1 462 most depleted sgRNAs (5 %) for
the CHP-212 cell line, more than 87,5 % were expressed with a FPKM >1.
Figure S6. MEK inhibitor MEK162 and EGFR inhibitor Erlotinib affected cell
viability of the respective cell lines. a,b) HCC-827 and CHP-212 cells were
treated with indicated concentrations of Erlotinib (a) or MEK162 (b) and
analyzed as described in M&M part. Figure S7. Cytogenetics of HCC-827
and CHP-212 cell lines. (PDF 1451 kb)
Additional file 2: Table S1. Correlation of sgRNA library distribution
between technical replicates in HCC-827 and CHP-212 cells. (XLSX 28 kb)
Additional file 3: Table S2. Correlation of sgRNA library distribution
between technical replicates of HCC-827 and CHP-212 cells. (XLSX 30 kb)
Additional file 4: Table S3. First 1 000 most depleted genes for
HCC-827 cell lines. This table shows the list of 1 000 most depleted
genes in the HCC-827 cells along with their sgRNA fold changes at the
days 14, 21 and 28. Gene expression of target genes is indicated as
average FPKMs across 3 replicates. Cumulative scores are calculated as
the sum of log2 FC scores obtained at either two or all three time points.
Genes are ranked by the cumulative score obtained at all three time
points (e.g. as the sum of log FC scores at days 14, 21 and 28 sorted in
ascending order). Essential genes identified in recent genetic screens are
reported. Genes expressed at low levels in the parental cell line (FPKM <
1) are highlighted in grey. (XLSX 127 kb)
Additional file 5: Table S4. First 1 000 most depleted genes for
CHP-212 cell lines. This table shows the list of 1 000 most depleted genes
in the CHP-212 cells along with their sgRNA fold changes at the days 14,
21 and 28. Gene expression of target genes is indicated as average
FPKMs across 3 replicates. Cumulative scores are calculated as the sum of
log2 FC scores obtained at either two or all three time points. Genes are
ranked by the cumulative score obtained at all three time points (e.g. as
the sum of log FC scores at days 14, 21 and 28 sorted in ascending
order). Essential genes identified in recent genetic screens are reported.
Genes expressed at low levels in the parental cell line (FPKM < 1) are
highlighted in grey. (XLSX 130 kb)
Additional file 6: Table S5. mRNA expression levels for kinases of top
the 20 list for HCC-827 cells. Expression of candidate genes was found to
be at very high level in the EGFR-mutant HCC-827 parental line, e.g.
128.09 FPKMs for EGFR. (XLSX 38 kb)
Additional file 7: Table S6. mRNA expression levels for kinases of top
the 20 list for CHP-212 cells. Several members of the RAS pathway from
the top-ranking hits were expressed at high levels in the parental
NRAS-mutant CHP-212 line, e.g. 12.03, 3.86 and 15.93 FPKMs for MAP2K1,
MAP2K6 and RAF-1 respectively. (XLSX 38 kb)
Additional file 8: Table S7. Top hits for the CHP-212 cell line including
genes that are not essential, not present in the top 1 000 for the
HCC-827 line, and ranked based on their cumulative screening score and
expression level. (XLSX 48 kb)
Additional file 9: Table S8. Top hits for the CHP-212 cell line including
genes that are not essential, not present in the top 1 000 for the HCC-827
line, and ranked based on their cumulative screening score and expression
level. (XLSX 45 kb)
Abbreviations
CRISPR: Clustered regularly interspaced short palindrome repeats;
sgRNA: Single guide RNA; DSB: Double-strand breaks; NHEJ: Nonhomologous
end-joining; indels: Insertions and deletions; EGFR: Epidermal growth factor
receptor
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